These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35372900)

  • 1. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
    Charytan DM; Hsu JY; Mc Causland FR; Waikar SS; Ikizler TA; Raj DS; Landis JR; Mehrotra R; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
    Kidney360; 2020 Dec; 1(12):1380-1389. PubMed ID: 35372900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
    Cohn JN; Johnson G; Ziesche S; Cobb F; Francis G; Tristani F; Smith R; Dunkman WB; Loeb H; Wong M
    N Engl J Med; 1991 Aug; 325(5):303-10. PubMed ID: 2057035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
    Zamani P; Akers S; Soto-Calderon H; Beraun M; Koppula MR; Varakantam S; Rawat D; Shiva-Kumar P; Haines PG; Chittams J; Townsend RR; Witschey WR; Segers P; Chirinos JA
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28219917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
    N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
    Charytan DM; Himmelfarb J; Ikizler TA; Raj DS; Hsu JY; Landis JR; Anderson AH; Hung AM; Mehrotra R; Sharma S; Weiner DE; Williams M; DiCarli M; Skali H; Kimmel PL; Kliger AS; Dember LM;
    Kidney Int; 2019 Apr; 95(4):973-982. PubMed ID: 30473139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial.
    Mc Causland FR; Claggett B; Sabbisetti VS; Jarolim P; Waikar SS
    Am J Kidney Dis; 2019 Oct; 74(4):483-490. PubMed ID: 31040088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension.
    Vannorsdall MD; Hariachar S; Hewitt LA
    Postgrad Med; 2015 Mar; 127(2):133-43. PubMed ID: 25708022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
    Fletcher RD; Cintron GB; Johnson G; Orndorff J; Carson P; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI49-55. PubMed ID: 8500239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT).
    Wiggers H; Køber L; Gislason G; Schou M; Poulsen MK; Vraa S; Nielsen OW; Bruun NE; Nørrelund H; Hollingdal M; Barasa A; Bøttcher M; Dodt K; Hansen VB; Nielsen G; Knudsen AS; Lomholdt J; Mikkelsen KV; Jonczy B; Brønnum-Schou J; Poenaru MP; Abdulla J; Raymond I; Mahboubi K; Sillesen K; Serup-Hansen K; Madsen JS; Kristensen SL; Larsen AH; Bøtker HE; Torp-Petersen C; Eiskjær H; Møller J; Hassager C; Steffensen FH; Bibby BM; Refsgaard J; Høfsten DE; Mellemkjær S; Gustafsson F
    Am Heart J; 2021 Jan; 231():137-146. PubMed ID: 33039340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate.
    Li H; Wang SX
    J Nephrol; 2011; 24(2):236-45. PubMed ID: 21240870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Preterm Labor by Isosorbide Dinitrate and Nitroglycerin Patch.
    Ghafarzadeh M; Shakarami A; Yari F
    Cardiovasc Hematol Disord Drug Targets; 2023; 23(2):130-135. PubMed ID: 37594102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.
    Nyolczas N; Dékány M; Muk B; Szabó B
    Adv Exp Med Biol; 2018; 1067():31-45. PubMed ID: 29086392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate.
    Adigun AQ; Ajayi OE; Sofowora GG; Ajayi AA
    Int J Cardiol; 1998 Nov; 67(1):81-6. PubMed ID: 9880204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of isosorbide dinitrate for the symptomatic treatment of patients with Chagas' disease achalasia. A double-blind, crossover trial.
    Ferreira-Filho LP; Patto RJ; Troncon LE; Oliveira RB
    Braz J Med Biol Res; 1991; 24(11):1093-8. PubMed ID: 1822997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
    Thadani U; Jacob RG
    Drugs Today (Barc); 2008 Dec; 44(12):925-37. PubMed ID: 19198701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
    Cohn JN; Archibald DG; Francis GS; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Flohr KH
    Circulation; 1987 May; 75(5 Pt 2):IV49-54. PubMed ID: 3552302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydralazine and isosorbide dinitrate: comparative central and regional hemodynamic effects when administered alone or in combination.
    Leier CB; Magorien RD; Desch CE; Thompson MJ; Unverferth DV
    Circulation; 1981 Jan; 63(1):102-9. PubMed ID: 7438384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.